A PHASE II MULTI-CENTRE, RANDOMIZED, OPEN LABEL STUDY OF MAINTENANCE THERAPY WITH SUBCUTANEOUS BORTEZOMIB TWICE MONTHLY ASSOCIATED WITH DEXAMETHASONE, IN RELAPSED AND REFRACTORY MULTIPLE MYELOMA PATIENTS AFTER SALVAGE WITH BORTEZOMIB-BASED THERAPY
Phase of Trial: Phase II
Latest Information Update: 12 May 2016
At a glance
- Drugs Bortezomib (Primary) ; Dexamethasone (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- 09 May 2016 Planned End Date changed from 1 Nov 2018 to 1 Nov 2020.
- 09 May 2016 Planned primary completion date changed from 1 Nov 2016 to 1 Nov 2017.
- 24 Mar 2015 Planned End Date changed from 1 Sep 2018 to 1 Nov 2018, as reported by ClinicalTrials.gov.